 |
200 Diseases |  |
191 Trials |
|
191 Trials |  |
19915 News |  |
| «12...192193194195196197198199200201202203204» |
- | GSK2800528 / GSK
Trial completion: A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability, Immunogenicity, and Pharmacodynamics (PD) of GSK2800528 in Healthy Subjects. (clinicaltrials.gov) - Apr 30, 2014
P1, N=45, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed
- || Humira (adalimumab) / Eisai, AbbVie
Observational data, P4 data, Trial initiation date: STRIVE: Juvenile Idiopathic Arthritis (JIA) Registry (clinicaltrials.gov) - Apr 29, 2014
P=N/A, N=800, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Initiation date: Jun 2008 --> Jul 2008
- || Enbrel (etanercept) / Pfizer, Amgen
Trial primary completion date: Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab (clinicaltrials.gov) - Apr 29, 2014
P4, N=100, Recruiting, Sponsor: Amgen
Initiation date: Jun 2008 --> Jul 2008 Trial primary completion date: Jul 2015 --> Nov 2016
- || Enbrel (etanercept) / Pfizer, Amgen
Trial completion date: Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab (clinicaltrials.gov) - Apr 29, 2014
P4, N=100, Recruiting, Sponsor: Amgen
Trial primary completion date: Jul 2015 --> Nov 2016 Trial completion date: Sep 2015 --> Jan 2017
- || Humira (adalimumab) / Eisai, AbbVie
Trial initiation date: Effectiveness and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice (clinicaltrials.gov) - Apr 22, 2014
P=N/A, N=5745, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Trial completion date: Sep 2015 --> Jan 2017 Initiation date: Sep 2003 --> Apr 2003
- ||||| Humira (adalimumab) / Eisai, AbbVie
Clinical: Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - Apr 21, 2014
P3, N=225, Not yet recruiting, Sponsor: AbbVie
Initiation date: Sep 2003 --> Apr 2003 Initiation date: Apr 2014 --> May 2014
- ||||| Xeljanz (tofacitinib) / Pfizer
Clinical: OPAL BROADEN: Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study (clinicaltrials.gov) - Apr 17, 2014
P3, N=400, Recruiting, Sponsor: Pfizer
Initiation date: Apr 2014 --> May 2014 Initiation date: Jan 2014 --> Jan 2014
- Humira (adalimumab) / Eisai, AbbVie
New P2 trial: Clinical Trial Using Humira in Netherton Syndrome (clinicaltrials.gov) - Apr 13, 2014
P2, N=23, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment change: Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment (clinicaltrials.gov) - Apr 10, 2014
P=N/A, N=52, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Initiation date: Jan 2014 --> Jan 2014 N=177 --> 52
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment (clinicaltrials.gov) - Apr 10, 2014
P=N/A, N=52, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
N=177 --> 52 Active, not recruiting --> Completed
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment change: Physical Activity in Patients With Rheumatoid Arthritis Treated With Adalimumab in Routine Clinical Practice (clinicaltrials.gov) - Apr 9, 2014
P=N/A, N=550, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed N=1000 --> 550
- || Humira (adalimumab) / Eisai, AbbVie
Observational data, P4 data, Enrollment change: Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis (clinicaltrials.gov) - Apr 9, 2014
P=N/A, N=555, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
N=1000 --> 550 N=800 --> 555
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: Special Investigation of Humira® (Adalimumab) on Long-term Treatment in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Apr 9, 2014
P=N/A, N=600, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
N=800 --> 555 Completed --> Active, not recruiting
- Humira (adalimumab) / Eisai, AbbVie
Biomarker, Trial initiation date: A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bowel Disease, Who Have Been Treated With Adalimumab and Who Developed Hepatosplenic T-Cell Lymphoma (clinicaltrials.gov) - Apr 9, 2014
P=N/A, N=40, Recruiting, Sponsor: AbbVie
Completed --> Active, not recruiting Initiation date: Mar 2013 --> Mar 2014
- Humira (adalimumab) / AbbVie
Enrollment change: Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial (clinicaltrials.gov) - Apr 9, 2014
P2, N=23, Completed, Sponsor: New York University School of Medicine
Initiation date: Mar 2013 --> Mar 2014 N=179 --> 23
- Humira (adalimumab) / AbbVie
Trial completion: Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial (clinicaltrials.gov) - Apr 9, 2014
P2, N=23, Completed, Sponsor: New York University School of Medicine
N=179 --> 23 Active, not recruiting --> Completed
- |||||| Plivensia (sirukumab) / J&J
Enrollment open, Monotherapy: SIRROUND-H: A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA (clinicaltrials.gov) - Apr 8, 2014
P3, N=510, Recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Humira (adalimumab) / Eisai, AbbVie, Tavalisse (fostamatinib) / Rigel, Kissei
Enrollment change, Monotherapy: OSKIRA -4: Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Apr 2, 2014
P2b, N=390, Terminated, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting N=280 --> 390
- Clinical: ABI-RA: Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk of Immunization in Rheumatoid Arthritis Patients or Juvenile Idiopathic Arthritis Patients (clinicaltrials.gov) - Apr 2, 2014
P=N/A, N=500, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment closed, Immunomodulating: Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab. (clinicaltrials.gov) - Mar 26, 2014
P=N/A, N=52, Active, not recruiting, Sponsor: University of North Carolina, Chapel Hill
N=280 --> 390 Recruiting --> Active, not recruiting
- fletikumab (NNC109-0012) / Novo Nordisk
New P2 trial, Biopsy: A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate (clinicaltrials.gov) - Mar 25, 2014
P2, N=42, Recruiting, Sponsor: Novo Nordisk A/S
- fletikumab (NNC109-0012) / Novo Nordisk
Enrollment open, Biopsy: A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate (clinicaltrials.gov) - Mar 23, 2014
P2, N=42, Recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Trial initiation date, HEOR: Evaluation of Health Costs and Resource Utilization (clinicaltrials.gov) - Mar 18, 2014
P4, N=160, Not yet recruiting, Sponsor: University of Western Ontario, Canada
Not yet recruiting --> Recruiting Initiation date: Dec 2013 --> Apr 2014
- Humira (adalimumab) / Eisai, AbbVie
Trial initiation date, Combination therapy: REACT2: Enhanced Algorithm for Crohn's Treatment Incorporating Early Combination Therapy (clinicaltrials.gov) - Mar 18, 2014
P4, N=1200, Enrolling by invitation, Sponsor: University of Western Ontario, Canada
Initiation date: Dec 2013 --> Apr 2014 Initiation date: Nov 2013 --> Mar 2014
- | Humira (adalimumab) / Eisai, AbbVie, Tavalisse (fostamatinib) / Rigel, Kissei
New P2b trial, Monotherapy, MRI: OSKIRA 4 SS: Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study (clinicaltrials.gov) - Mar 18, 2014
P2b, N=198, Terminated, Sponsor: AstraZeneca
- Humira (adalimumab) / Eisai, AbbVie
Enrollment open, Combination therapy: REACT2: Enhanced Algorithm for Crohn's Treatment Incorporating Early Combination Therapy (clinicaltrials.gov) - Mar 18, 2014
P4, N=1200, Enrolling by invitation, Sponsor: University of Western Ontario, Canada
Initiation date: Nov 2013 --> Mar 2014 Not yet recruiting --> Enrolling by invitation
- ||| Humira (adalimumab) / AbbVie
HEOR: Fecal Calprotectin Levels, Quality of Life, and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - AdaProQuo (clinicaltrials.gov) - Mar 18, 2014
P=N/A, N=70, Not yet recruiting, Sponsor: AbbVie
- ||||| Xeljanz (tofacitinib) / Pfizer, Enbrel (etanercept) / Pfizer, Amgen
Clinical: Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 18, 2014
P4, N=4000, Recruiting, Sponsor: Pfizer
- Humira (adalimumab) / Eisai, AbbVie
Biomarker: A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bowel Disease, Who Have Been Treated With Adalimumab and Who Developed Hepatosplenic T-Cell Lymphoma (clinicaltrials.gov) - Mar 12, 2014
P=N/A, N=40, Recruiting, Sponsor: AbbVie
- |||||| Humira (adalimumab) / AbbVie
Enrollment open: SERENE-UC: Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - Mar 10, 2014
P3, N=605, Recruiting, Sponsor: AbbVie
Not yet recruiting --> Enrolling by invitation Not yet recruiting --> Recruiting
- Orencia (abatacept) / BMS, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial initiation date: SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug. (clinicaltrials.gov) - Mar 4, 2014
P4, N=477, Recruiting, Sponsor: Julia Brown
Not yet recruiting --> Recruiting Initiation date: Mar 2011 --> Aug 2011
- Orencia (abatacept) / BMS, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment change: SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug. (clinicaltrials.gov) - Mar 4, 2014
P4, N=477, Recruiting, Sponsor: Julia Brown
Initiation date: Mar 2011 --> Aug 2011 N=870 --> 477
- Orencia (abatacept) / BMS, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment open: SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug. (clinicaltrials.gov) - Mar 4, 2014
P4, N=477, Recruiting, Sponsor: Julia Brown
N=870 --> 477 Not yet recruiting --> Recruiting
- |||||| Humira (adalimumab) / AbbVie
Enrollment open: Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease (clinicaltrials.gov) - Mar 2, 2014
P3, N=300, Recruiting, Sponsor: AbbVie
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: CLASSICII: Remission in Subjects With Crohn's Disease, 1 Year Phase (clinicaltrials.gov) - Feb 22, 2014
P3, N=276, Completed, Sponsor: Abbott
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA) (clinicaltrials.gov) - Feb 22, 2014
P3, N=171, Completed, Sponsor: Abbott
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Humira (adalimumab) / AbbVie
Trial completion: ATLAS: Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis (clinicaltrials.gov) - Feb 22, 2014
P3, N=315, Completed, Sponsor: Abbott
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Humira (adalimumab) / AbbVie
Trial completion: CHARM: Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease (clinicaltrials.gov) - Feb 22, 2014
P3, N=854, Completed, Sponsor: Abbott
Active, not recruiting --> Completed No longer recruiting --> Completed
- || Humira (adalimumab) / AbbVie
Enrollment closed, IO biomarker: An Observational Study of Fecal Calprotectin as Clinical Tool in Monitoring Moderate-to-severe Crohn's Disease on Adalimumab Induction Therapy: a KoRean Experience (FAIR) (clinicaltrials.gov) - Feb 18, 2014
P=N/A, N=100, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
No longer recruiting --> Completed Enrolling by invitation --> Active, not recruiting
- ||||||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: PIONEER I: Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa (clinicaltrials.gov) - Feb 18, 2014
P3, N=309, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Enrolling by invitation --> Active, not recruiting Active, not recruiting --> Completed
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
New P3 trial: Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - Feb 17, 2014
P3, N=225, Not yet recruiting, Sponsor: AbbVie
- | Humira (adalimumab) / Eisai, AbbVie
Enrollment open: Adalimumab Intralesional in Intestinal Strictures of Crohn's Disease Patients (clinicaltrials.gov) - Feb 17, 2014
P3, N=102, Recruiting, Sponsor: Sara Varea
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| Humira (adalimumab) / AbbVie
New P3 trial: Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease (clinicaltrials.gov) - Feb 17, 2014
P3, N=300, Recruiting, Sponsor: AbbVie
- |||||||||| Humira (adalimumab) / AbbVie
New P3 trial: SERENE-UC: Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - Feb 17, 2014
P3, N=605, Recruiting, Sponsor: AbbVie
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment closed, Adherence: Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice (clinicaltrials.gov) - Feb 15, 2014
P=N/A, N=80, Active, not recruiting, Sponsor: AbbVie
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| Enbrel (etanercept) / Pfizer, Amgen
Enrollment open: ANTIBODY-RA: Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab (clinicaltrials.gov) - Feb 13, 2014
P4, N=600, Recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||| Humira (adalimumab) / Eisai, AbbVie
Enrollment open: A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis (clinicaltrials.gov) - Feb 12, 2014
P3, N=200, Recruiting, Sponsor: AbbVie
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- pateclizumab (RG7416) / Roche
Trial completion, Combination therapy: A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - Feb 9, 2014
P2, N=211, Completed, Sponsor: Genentech
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Trial completion: Anti-TNF Agents for the Treatment of Rheumatoid Arthritis (clinicaltrials.gov) - Feb 9, 2014
P4, N=63, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Recruiting --> Completed
- Humira (adalimumab) / Eisai, AbbVie
Enrollment change: MB: Metabolomic Analysis, a Potential Tool to Direct Treatment With Adalimumab in Crohn's Disease (CD) (clinicaltrials.gov) - Feb 3, 2014
P=N/A, N=25, Completed, Sponsor: Martin Storr
Recruiting --> Completed N=50 --> 25